David A. Siegel Elevation Oncology, Inc. Transaction History
Two Sigma Advisers, LP
- $42.8 Billion
- Q1 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Elevation Oncology, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 193,100 shares of ELEV stock, worth $73,378. This represents 0.0% of its overall portfolio holdings.
Number of Shares
193,100
Previous 84,400
128.79%
Holding current value
$73,378
Previous $48,000
4.17%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ELEV
# of Institutions
73Shares Held
33.2MCall Options Held
65KPut Options Held
4K-
Frazier Life Sciences Management, L.P. Menlo Park, CA5.99MShares$2.28 Million0.1% of portfolio
-
Bml Capital Management, LLC Zionsville, IN5.89MShares$2.24 Million1.24% of portfolio
-
Tang Capital Management LLC San Diego, CA4.76MShares$1.81 Million0.08% of portfolio
-
Aisling Capital Management LP New York, NY2.83MShares$1.08 Million0.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.59MShares$982,3830.0% of portfolio
About Elevation Oncology, Inc.
- Ticker ELEV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,300,900
- Market Cap $8.85M
- Description
- Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...